Shelter Ins Retirement Plan Sells 6,000 Shares of Pfizer Inc. (PFE)

Shelter Ins Retirement Plan lowered its position in Pfizer Inc. (NYSE:PFE) by 5.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 113,900 shares of the biopharmaceutical company’s stock after selling 6,000 shares during the quarter. Pfizer comprises approximately 1.9% of Shelter Ins Retirement Plan’s portfolio, making the stock its 26th largest holding. Shelter Ins Retirement Plan’s holdings in Pfizer were worth $4,066,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Northstar Group Inc. increased its stake in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. increased its stake in Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its stake in Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC increased its stake in Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 55 shares during the last quarter. Finally, Meridian Wealth Management LLC increased its stake in Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 57 shares during the last quarter. 69.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pfizer Inc. (NYSE PFE) opened at $36.93 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market cap of $220,130.00, a PE ratio of 22.66, a PEG ratio of 2.29 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 earnings per share. research analysts predict that Pfizer Inc. will post 2.6 EPS for the current year.

Pfizer announced that its Board of Directors has approved a stock buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio is currently 78.53%.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,450 shares of company stock valued at $1,065,220. 0.06% of the stock is currently owned by company insiders.

A number of research analysts recently commented on PFE shares. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. Barclays set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $38.12.

TRADEMARK VIOLATION NOTICE: “Shelter Ins Retirement Plan Sells 6,000 Shares of Pfizer Inc. (PFE)” was published by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2018/01/23/shelter-ins-retirement-plan-sells-6000-shares-of-pfizer-inc-pfe-3.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply